IGC Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	2023	2022	2021	2020	2019	2018 - 2005
Net Income	-13	-11.51	-15.02	-8.81	-7.32	Upgrade
Depreciation & Amortization	0.64	0.66	0.65	0.48	0.14	Upgrade
Share-Based Compensation	1.77	2.84	2.2	0.66	0.77	Upgrade
Other Operating Activities	5.39	0.96	4.71	-3.13	-2.28	Upgrade
Operating Cash Flow	-5.2	-7.05	-7.46	-10.8	-8.68	Upgrade
Capital Expenditures	-0.09	0.23	-0.21	-1.47	-4.39	Upgrade
Change in Investments	0.15	-0.15	0	4.98	-5.08	Upgrade
Other Investing Activities	-0.38	-0.31	-0.54	-0.12	-0.08	Upgrade
Investing Cash Flow	-0.32	-0.24	-0.74	3.39	-9.55	Upgrade
Share Issuance / Repurchase	3.53	0.1	4.15	14.16	-0.06	Upgrade
Debt Issued / Paid	-0	-0	-0	0.53	0	Upgrade
Financing Cash Flow	3.52	0.1	4.14	14.69	-0.06	Upgrade
Exchange Rate Effect	-0.01	-0.08	-0.03	0.02	-0.07	Upgrade
Net Cash Flow	-2	-7.26	-4.09	7.29	-18.35	Upgrade
Free Cash Flow	-5.29	-6.82	-7.67	-12.27	-13.07	Upgrade
Free Cash Flow Margin	-393.53%	-748.52%	-1931.74%	-1366.37%	-320.87%	Upgrade
Free Cash Flow Per Share	-0.09	-0.13	-0.15	-0.29	-0.33	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).